• 1:中国医师协会心血管内科医师分会结构性心脏病专业委员会
• 2:中国医师协会心血管内科医师分会心力衰竭专业委员会
• 3:中国医师协会心血管外科医师分会结构性心脏病专业委员会
• 4:中国医师协会心血管外科医师分会心血管麻醉与重症专业委员会

摘要(Abstract)：

<正>11心力衰竭概述心力衰竭是各种原因所致心肌病变发展到最终的共同表现。流行病学数据显示,仅美国就有620万成年心力衰竭患者[1],我国由于人口基数巨大,心力衰竭患者人群逾千万[2]。若无有效的治疗,慢性心力衰竭5年生存率低于50%,急性心力衰竭5年死亡率高达60%[3]。根据目前指南,心力衰竭可分为三类,即射血分数降低的心力衰竭(heart failure with reduced ejection fraction,HFrEF)、

关键词(KeyWords)： 射血分数保留的心力衰竭;房间隔分流器;左心房超负荷;器械治疗

Abstract:

Keywords:

基金项目(Foundation):

作者(Author):

参考文献(References)：

• [1]Virani SS,Alonso A,Benjamin EJ,et al.Heart disease and stroke statistics-2020 update:a report from the American Heart Association.Circulation,2020,141(9):e139-e596.
• [2]Hao G,Wang X,Chen Z,et al.Prevalence of heart failure and left ventricular dysfunction in China:the China Hypertension Survey,2012-2015.Eur J Heart Fail,2019,21(11):1329-1337.
• [3]中国医师协会急诊医师分会,中国心胸血管麻醉学会急救与复苏分会.中国急性心力衰竭急诊临床实践指南(2017).中华急诊医学杂志,2017,26(12):1347-1357.
• [4]Yancy CW,Jessup M,Bozkurt B,et al.2017 ACC/AHA/HFSA focused update of the 2013 ACCF/AHA guideline for the management of heart failure:A report of the American College of Cardiology/American Heart Association task force on clinical practice guidelines and the heart failure society of America.Circulation,2017,136(6):e137-e161.
• [5]Hollenberg SM,Stevenson LW,Ahmad T,et al.2019 ACC expert consensus decision pathway on risk assessment,management,and clinical trajectory of patients hospitalized with heart failure:A report of the American College of Cardiology Solution Set Oversight Committee.J Am Coll Cardiol,2019,74(15):1966-2011.
• [6]Zhang Yh,Zhang J,Butler J,et al.Contemporary Epidemiology,Management,and Outcomes of Patients Hospitalized for Heart Failure in China:Results From the China Heart Failure(China-HF)Registry.J Card Fail,2017,23(12):868-875.
• [7]Shah SJ,Borlaug BA,Kitzman DW,et al.Research priorities for heart failure with preserved ejection fraction:National Heart,Lung,and Blood Institute Working Group Summary.Circulation,2020,141(12):1001-1026.
• [8]SidneyS,Go AS,Jaffe MG,et al.Association between aging of the US population and heart disease mortality from 2011 to 2017.JAMA Cardiol,2019,4(12),1280-1286.
• [9]廖玉华,杨杰孚,张健,等.舒张性心力衰竭诊断和治疗专家共识.临床心血管病杂志,2020,36(1):1-10.
• [10]Reddy YNV,Borlaug BA,O'Connor CM,et al.Novel approaches to the management of chronic systolic heart failure:future directions and unanswered questions.Eur Heart J,2020,41(18):1764-1774.
• [11]国家卫生计生委合理用药专家委员会,中国药师协会.心力衰竭合理用药指南(第2版).中国医学前沿杂志(电子版),2019,11(7):1-78.
• [12]Dorfs S,Zeh W,Hochholzer W,et al.Pulmonary capillary wedge pressure dur-ing exercise and long-term mortality in patients with suspected heart failure with preserved ejection fraction.Eur Heart J,2014,35(44):3103-3112.
• [13]Rahimi K,Bennett D,Conrad N,et al.Risk prediction in patients withheartfailure:a systematic review and analysis.JACC Heart Fail,2014,2(5):440-446.
• [14]Kaye D,Shah SJ,Borlaug BA,et al.Effects of an interatrial shunt on rest and exercise hemodynamics:results of a computer simulation in heart failure.J Card Fail.2014,20(3):212-221.
• [15]S?ndergaard L,Reddy V,Kaye D,et al.Transcatheter treatment of heart failure with preserved or mildly reduced ejection fraction using a novel interatrial implant to lower left atrial pressure.Eur J Heart Fail,2014,16(7):796-801.
• [16]Hasenfug G,Hayward C,Burkhoff D,et al.A transcatheter intracardiac shunt device for heart failure with preserved ejection fraction(REDUCE LAP-HF):a multicentre,open-label,singlearm,phase 1 trial.Lancet,2016,387(10025):1298-1304.
• [17]Kaye DM,HasenfuβG,Neuzil P,et al.One-year outcomes after transcatheter insertion of an interatrial shunt device for the management of heart failure with preserved ejection fraction.Circ Heart Fail,2016,9(12):e003662.
• [18]Kaye DM,Petrie MC,Mckenzie S,et al.Impact of an interatrial shunt device on survival and heart failure hospitalization in patients with preserved ejection fraction.ESC Heart Failure,2019,6(1):62-69.
• [19]Meta-analysis Global Group in Chronic Heart Failure(MAGGIC).The survival of patients with heart failure with preserved or reduced left ventricular ejection fraction:an individual patient data metaanalysis.Eur Heart J,2012,33(14):1750-1757.
• [20]Pocock SJ,Ariti CA,McMurray JJ,et al.Predicting survival in heart failure:a risk score based on 39 372 patients from 30 studies.Eur Heart J,2013,34(19):1404-1413.
• [21]Sartipy U,Dahlstrom U,Edner M,et al.Predicting survival in heart failure:validation of the MAGGIC heart failure risk score in51,043 patients from the Swedish heart failure registry.Eur J Heart Fail,2014,16(2):173-179.
• [22] Feldman T,Mauri L,Kahwash R,et al Transcatheter interatrial shunt device for the treatment of heart failure with preserved ejection fraction(REDUCE LAP-HF I[Reduce Elevated Left Atrial Pressure in Patients With Heart Failure]).Circulation,2018,137(4):364-375.
• [23]Shah SJ,Ted F,Ricciardi MJ,et al.One-year safety and clinical outcomes of a transcatheter interatrial shunt device for the treatment of heart failure with preserved ejection fraction in the reduce elevated left atrial pressure in patients with heart failure(REDUCE LAP-HF I)trial.JAMA Cardiology,2018,3(10):968-977.
• [24]Rajeshkumar R,Pavithran S,Sivakumar K,et al.Atrial septostomy with a predefined diameter using a novel occlutech atrial flow regulator improves symptoms and cardiac index in patients with severe pulmonary arterial hypertension.Catheter Cardiovasc Interv,2017,90(7):1145-1153.
• [25]Paitazoglou C,Ozdemir R,Pfister R,et al.The APR-PRELIEVE trial:a prospective,non-randomised,pilot study to assess the Atrial Flow Regulator(AFR)in heart failure patients with either preserved or reduced ejection fraction.EuroIntervention,2019,15(5):403-410.
• [26]Trigo MD,Bergeron S,Bernier M,et al.Unidirectional left-to-right interatrial shunting for treatment of patients with heart failure with reduced ejection fraction:a safety and proof-of-principle cohort study.Lancet,2016,387(10025):1290-1297.
• [27]Rodes-Cabau J,Bernier M,Amat-Santos IJ,et al.Interatrial shunting for heart failure:early and late results from the firstin-human experience with the V-wave system.JACC Cardiovasc Interv,2018,11(22):2300-2310.
• [28]Guimaraes L,Bergeron S,Bernier M,et al.Initial experience with the second-generation v-wave shunt for treating Patients with chronic heart failure.Eurointervention.2020,15(16):1426-1428.
• [29]尚小珂,张长东,陈澍,等.D-Shant心房分流器的初步动物实验研究.中国介入心脏病学杂志,2020,28(6):337-342.
• [30]尚小珂,陈澍,董念国,等.治疗心力衰竭的新型器械——心房分流器的研究进展.中国介入心脏病学杂志,2020,28(5):274-276.
• [31]廖曼,尚小珂,张长东,等.心房分流术治疗心力衰竭的研究进展.临床心血管病杂志,2020,321(3):27-32.